The medtech industry continues to climb back up in the markets, following a landmark week with another move up toward its pre-COVID-19-pandemic highs. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.29 points at the end of last week (July 24). That total represents just a […]
NeuroMetrix improves bottom line despite nearly halved Q2 sales
NeuroMetrix (NSDQ:NURO) shares dipped today after posting second-quarter results that reflected the effects of the COVID-19 pandemic. The Woburn, Mass.-based pain-treating transcutaneous electrical nerve stimulation (TENS) device developer posted losses of -$851,944 on sales of $$1.4 million for the three months ended June 30, 2020, for a 74.7% bottom-line gain on a sales decline of 42.2%. […]
MedTech 100 roundup: Medtech stocks hit highest point since early March
Medtech stocks generally ended last week at their highest point in more than a month — even as the COVID-19 pandemic continues to cause economic havoc. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 82.3 points at the end of last week (April 24). That […]
NeuroMetrix dips on Q1 losses
NeuroMetrix (NSDQ:NURO) shares fell today on first-quarter losses that reflected the impact of COVID-19 on its business. The Woburn, Mass.-based pain-treating transcutaneous electrical nerve stimulation (TENS) device developer posted losses of -$657,371 on sales of $2.2 million for the three months ended March 31, 2020, seeing its bottom line slide into the red from profits of […]
NeuroMetrix settles $4m false advertising case with FTC
Pain-treating TENS device company NeuroMetrix (NSDQ:NURO) has agreed to pay at least $4 million to settle a false advertising case brought by the Federal Trade Commission FTC. The commission said today that the Woburn, Mass.-based company also agreed to stop making deceptive claims that its Quell device treats pain throughout the body when placed below the […]
NeuroMetrix CEO cuts his salary to $1
Dr. Shai N. Gozani, CEO of pain-treating TENS device company NeuroMetrix (NSDQ:NURO), is cutting his annual salary to $1 from a previous $422,200 — accepting a stock option to purchase 100,000 shares instead. The 2020 executive compensation package, approved Dec. 29 by the company board’s compensation committee, also cuts salaries in return for stock options for […]
How NeuroMetrix seeks to better relieve pain with AI
NeuroMetrix plans to add artificial intelligence to the latest iteration of its Quell transcutaneous electrical nerve stimulation (TENS) device. AI will allow Quell 2.0 to tailor treatment to each individual user, according to the Waltham, Mass.–based based company. Launched in September 2018 Quell 2.0 is 50% smaller and 20% more powerful than the original Quell, […]
NeuroMetrix lands $4m milestone payment from GSK deal
NeuroMetrix (NSDQ:NURO) said this week that it reeled in a $3.8 million milestone payment from its collaboration with GlaxoSmithKline‘s (NYSE:GSK) consumer healthcare unit. The strategic deal between the two groups was first announced in January this year. According to the terms of the deal, GSK acquired exclusive ownership of NeuroMetrix’s Quell pain-relief device outside the U.S., in exchange for […]
Teardown: Inside the Neurometrix Quell TENS device
A TENS device for transcutaneous electrical nerve stimulation wraps around the upper calf much like a wristwatch wraps around the wrist. Here are some of its operational secrets. By Lee Teschler A medical device called a Quell performs what’s called transcutaneous electrical nerve stimulation on the lower leg. This technique is said to relieve diabetic pain. None […]
NeuroMetrix inks Quell ownership deal with GlaxoSmithKline, posts Q1 earnings
NeuroMetrix (NSDQ:NURO) today saw shares fall despite announcing an exclusive deal giving GlaxoSmithKline (NYSE:GSK) ownership of its Quell technology for commercialization outside the US and releasing Street-beating first quarter earnings. In its deal with GlaxoSmithKline, Waltham, Mass.-based NeuroMetrix said it will receive payments totaling $26.5 million, with $5 million paid at closing and up to $21.5 million […]
NeuroMetrix touts Quell user-response study data
NeuroMetrix (NSDQ:NURO) yesterday released results from a clinical study of its Quell wearable device, touting its ability to treat chronic pain. Results from the trial were published in the Journal of Pain Research, the Waltham, Mass.-based company said. In the retrospective study, researchers examined data from 713 subjects using its Quell device to treat chronic pain […]
- 1
- 2
- 3
- …
- 9
- Next Page »
